Patients w/ bleeding diatheses, thrombocytopenia or taking anticoagulant treatment. Thromboembolic events in women w/ advanced breast cancer. Inj site related events (eg, sciatica, neuralgia, neuropathic pain, & peripheral neuropathy). Administration at dorsogluteal inj site. Potential risk of osteoporosis. May interfere w/ Ab based-estradiol assays & may result in falsely increased levels of estradiol. May impair ability to drive or operate machinery due to asthenia. Mild to moderate hepatic impairment. Severe renal impairment (CrCl <30 mL/min). Women of childbearing potential should use effective contraception during treatment & for 2 yr after the last dose. Discontinue breastfeeding during treatment. Not recommended for use in childn & adolescents.
Sign Out
